source
- Pfizer secures up to $1.5 billion from Blackstone to fund berobenatide obesity drug developmentPfizer announced a financing arrangement with Blackstone Life Sciences that could provide up to $1.5 billion to support the development of berobenatide, an obesity drug acquired from Metsera. The…
- Parker Institute chief urges renewed focus on cancer immunotherapy after mixed results from Revolution Medicines' drugIra Mellman, who leads research at the Parker Institute for Cancer Immunotherapy, said on Sept. 16, 2026 that he felt disappointment and frustration as the industry celebrated Revolution Medicines'…